U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Refractory Splenic Marginal Zone Lymphoma

MedGen UID:
167791
•Concept ID:
C0856023
•
Neoplastic Process
Synonym: Refractory Splenic Marginal Zone B-Cell Lymphoma

Definition

Splenic marginal zone lymphoma that is resistant to treatment. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVRefractory Splenic Marginal Zone Lymphoma

Professional guidelines

PubMed

Marginal zone lymphoma: 2023 update on diagnosis and management.
Cheah CY, Seymour JF
Am J Hematol 2023 Oct;98(10):1645-1657. Epub 2023 Aug 21 doi: 10.1002/ajh.27058. PMID: 37605344
Contemporary management of nodal and primary splenic marginal zone lymphoma.
Leslie LA, Feldman TA, McNeill A, Timberg M, Iida H, Goy AH
Expert Rev Hematol 2019 Dec;12(12):1011-1022. Epub 2019 Nov 12 doi: 10.1080/17474086.2020.1681962. PMID: 31619091
Treatment of splenic marginal zone lymphoma: splenectomy versus rituximab.
Bennett M, Schechter GP
Semin Hematol 2010 Apr;47(2):143-7. doi: 10.1053/j.seminhematol.2010.01.004. PMID: 20350661

Recent clinical studies

Therapy

Refractory Splenic Marginal Zone Lymphoma Responsive to Combination Venetoclax and Bortezomib (Velcade) (V(2)) Therapy.
Roche KC, DeRosa PA, Liu ML, Nava VE, Aggarwal A
Curr Oncol 2022 Jun 6;29(6):4117-4124. doi: 10.3390/curroncol29060328. PMID: 35735437Free PMC Article
Anti-CD20 rechallenge with ofatumumab in relapsed/refractory splenic marginal zone lymphoma: the MORE trial.
Scarfò L, Ferrari S, Frustaci AM, Tani M, Bari A, Scarano E, Colia M, Ranghetti P, Angelillo P, Ronchi P, Ponzoni M, Ferreri AJM, Ghia P
Blood Adv 2022 Sep 27;6(18):5356-5359. doi: 10.1182/bloodadvances.2022007138. PMID: 35613463Free PMC Article
Activity of rituximab monotherapy in refractory splenic marginal zone lymphoma complicated with autoimmune hemolytic anemia.
Fabbri A, Gozzetti A, Lazzi S, Lenoci M, D'Amuri A, Leoncini L, Lauria F
Clin Lymphoma Myeloma 2006 May;6(6):496-9. doi: 10.3816/CLM.2006.n.033. PMID: 16796783

Prognosis

Refractory Splenic Marginal Zone Lymphoma Responsive to Combination Venetoclax and Bortezomib (Velcade) (V(2)) Therapy.
Roche KC, DeRosa PA, Liu ML, Nava VE, Aggarwal A
Curr Oncol 2022 Jun 6;29(6):4117-4124. doi: 10.3390/curroncol29060328. PMID: 35735437Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...